Charles C. Tong, PhD

Placeholder Person Graphic
Suzhou Ribo Life Science Co., Ltd.
Executive Vice President and Head of the R&D
Charles C. Tong, PhD, is Executive Vice President and Head of the R&D Center at Suzhou Ribo Life Science and is engaged in oligonucleotide drug development. Charles has more than 25 years of drug development working experience in the pharmaceutical industry. Previously, he was a Senior Director of Pharmaceutical Sciences at Pfizer. He is an active member of the ISPE China Leadership Committee. He served as Chair for ISPE China in 2013 and 2014. His interest has been mainly focused on pharmaceutical sciences, pharmaceutical development, and regulatory CMC. He earned his PhD in chemistry from Georgia Institute of Technology. Charles has been an ISPE member since 2008.

Related Articles

Evolving China’s Regulatory System in Alignment with ICH
Features
Evolving China’s Regulatory System in Alignment with ICH

With the Chinese government initiating drug regulatory reform in 2015 and China joining the International Council for Harmonisation (ICH) in 2017, a significant number of measures have been implemented by the government. The aim is to make fundamental changes to China’s drug regulatory administration system so it can facilitate pharmaceutical development and better meet patient needs in the...

Current State of Oligonucleotide Therapeutics
Features
Current State of Oligonucleotide Therapeutics

Oligonucleotides are a relatively new class of drugs, composed of natural and synthetic nucleotides, which primarily include small interfering RNA (siRNA), micro RNA (miRNA), and antisense oligonucleotide (ASO). These molecules achieve therapeutic effects through RNA interference, degradation, or splice-modulating pathways.1